Hadron Therapy Market - Forecast(2024 - 2030)

Hadron Therapy Market Overview

Hadron Therapy Market size is estimated at $1.1 billion in 2020, projected to grow at a CAGR of 8.7% during the forecast period 2021-2026. Hadron therapy, also known as ion beam therapy, is a form of cancer treatment that uses fast ionizing electromagnetic radiations. Charged particles or high-energy photons, such as protons, carbon, and other ions, make up these ionizing electromagnetic radiations. Owing to their radiobiological and physical properties, such as low diffusion, charged photon particles penetrate human body tissues and kill cancerous cells with maximum energy driving hadron therapy industry. As compared to other approaches, laser-based Hadron therapy techniques, Borated polyethylene are appealing owing to their compactness in creating miniaturized particle plasma accelerators and their ability to sustain a more powerful electric field. By killing the cancerous cells DNA strands, hadron therapy kills them. It is a more advanced treatment than conventional chemotherapy as it offers long-term cancer protection, has fewer side effects, and is effective against a wider range of cancer types and new-borns. Hadron therapy has also piqued clinician’s interest in pediatric oncology, Plasma accelerators, Borated polyethylene along with increasing techniques where long-term side effects can be a major concern for patients and their caregivers. The use of protons (or carbon) instead of X-rays in proton (or carbon therapy) confers some advantages on the procedure. Electron beams, neutron beams, beta particle beams, and alpha particle beams are some of the other common forms of particle electromagnetic radiation are expected to boost the overall market demand for Hadron Therapy Industry.

Hadron Therapy Market Report Coverage

The report: “Hadron Therapy Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Hadron Therapy Market.

By Type: Alpha Particle Beam, Beta Particle Beam, Neutron Particle Beam, Electron Particle Beam, Carbon Particle Beam and Proton Particle Beam.
By Application: Bone and Soft Tissue Cancer, Eye Cancer, Prostate Cancer, Liver Cancer, Lung Cancer, Pediatric Cancer and Others.
By End User: Hospitals, Ambulatory Surgical Centres and Cancer Research Institutes.
By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).

Key Takeaways

• The rising incidence of solid tumor in vital organs, as well as the rising morbidity and mortality rates associated with cancer is aiding the need for cutting-edge treatment methods around the globe, is expected to drive demand for Hadron Therapy.
• Geographically, North America Hadron Therapy Market held the largest revenue share of 38% in 2020 owing to the involvement of potential players who are developing innovative products, high investments in R&D and support of government investments in healthcare.
• The Hadron Therapy Industry is being driven by technological advances in oncology care that have helped to reduce the negative effects of electromagnetic radiation therapy on healthy tissues.
• The rising incidence and prevalence of cancer and healthcare expenditure is further driving growth in the Hadron Therapy industry.

 Hadron Therapy Market: Market Share (%) by Region, 2020

Hadron Therapy Market Segment Analysis - By Type

Based on Type, Hadron Therapy Market is segmented into Alpha Particle Beam, Beta Particle Beam, Neutron Particle Beam, Electron Particle Beam, Carbon Particle Beam and Proton Particle Beam. Alpha Particle Beam accounted for the largest revenue market share in 2020 owing to increased awareness of the potential benefits of targeted alpha therapy, as well as the increasing number of patients with cardiac and cancer ailments. Physicians may be able to administer highly efficient and accurate doses of protons to the exact location of lung cancer using proton Borated polyethylene therapy for lung cancer treatment. For patients with lung cancer that is confined to the chest, proton therapy has proved to be a viable treatment option such as plasma accelerators, borated polyethylene. For instance, Mevion and medPhoton GmbH formed a strategic partnership in May 2017 to combine medPhoton's ImagingRing with the MEVION S250i with HYPERSCAN system to provide precise and efficient care aids to Hadron Therapy Industry expansion. Proton Particle Beam segment is anticipated to grow with the fastest CAGR of 9.1% in the forecast period 2021-2026 owing to high degree of precision, shorter treatment time, and decreased side-effects associated with proton therapy as opposed to traditional photon therapies using X-rays account for the significant share of the proton therapy segment. As a result, there is a strong demand for Acute Hadron Therapy among healthcare providers and patients, which drives the Hadron Therapy Industry. High accuracy and minimize the risk of side effects are the factors attributed to the fastest growth of the segment.

Hadron Therapy Market Segment Analysis – By Application

Based on Application, Hadron Therapy Market is segmented into Bone and Soft Tissue Cancer, Eye Cancer, Liver Cancer, Prostate Cancer, Lung Cancer, Pediatric Cancer and Others. Lung Cancer accounted for the largest revenue market share in 2020. Physicians may be able to administer highly efficient and accurate doses of protons to the exact position of the lung cancer using proton therapy for lung cancer treatment. For patients with lung cancer that is confined to the abdomen, proton therapy tends to be a viable option. Lung cancer is a lethal lung solid tumor characterized by uncontrolled cell growth in the lung tissues. The most significant risk factor for lung cancer is cigarette smoking. Lung cancer may also be caused by prolonged exposure to cigarette smoke leading to market growth. According to Cancer Research UK data from 2017, NSCLC accounts for about 87 percent of lung cancers in the UK. Lung cancer accounts for roughly 13% of all new cancer diagnoses, according to the American Society of Clinical Oncology's 2019 survey driving the segment growth. Prostate Cancer segment is anticipated to grow with the fastest CAGR of 9.5% during the forecast period 2021-2026 This is owing to an increase in the incidence of the disease, a boom in generic medications, increased public concern about prostate cancer care, increased R&D spending by drug innovators, strong emerging pipeline medicines, and the availability of hadron cancer therapies, thereby, expanding the Hadron Therapy Market.

Hadron Therapy Market Segment Analysis - By Geography

Based on Geography, North America Hadron Therapy Market accounted for the 38% revenue share in 2020 owing towards the presence of several key players in the region. The high prevalence of cancer diseases like solid tumors, especially in the United States, will provide numerous opportunities for companies operating in this region to expand. Furthermore, the presence of appropriate insurance reimbursement programs in this region will contribute to a greater acceptance of cancer diseases aiding towards the Hadron Therapy Industry. Asia-Pacific is predicted to be the fastest growing region during the forecast period 2021- 2026 owing towards an increase in prostate cancer care awareness and the acceptance of prostate cancer treatment products. Furthermore, advances in healthcare infrastructure, an increase in the number of hospitals with advanced medical facilities like Plasma accelerators, Borated polyethylene, a growing R&D industry, increased healthcare reforms, and technological advancements in the field of healthcare is driving the market growth. Adoption of new technology, improved healthcare infrastructure, and increased market player investments in the production of immunotherapies and targeted therapies, resulting in a robust pipeline, are all expected to drive growth in the Asia Pacific region. Major players in China are working together with local and government agencies, such as the Chinese Urological Association, to conduct cancer research driving the regional growth.

Hadron Therapy Market Drivers

The Increasing Incidences Of Cancer Diseases:

The market is anticipated to evolve owing the increasing incidence of various cancer types among the global population, eventually leading to rise of Hadron therapy. The rising prevalence of solid tumors in vital organs, as well as the rising cancer morbidity and mortality rates are driving the market for cutting-edge treatment technologies like Plasma accelerators, Electromagnetic radiation and Borated polyethylene. The market for Hadron therapies has risen as a result of this. Increased data exchange in cancer treatment and cancer research has benefited the global hadron therapy market's growth trajectory. Hundreds of clinical trials have been conducted in recent years to prove the superiority of hadron therapy over other radiotherapies. Carbon therapy, in particular, has piqued the interest of scientists, aiding growth towards the Hadron Therapy Market.

Hadron Therapy Market Challenges

Decline In The Number Of Healthcare Employees:

The market's development is projected to be hampered by a shortage of doctors and nurses. For instance, the World Health Organization (WHO) estimates that India is short 600,000 doctors and 2 million nurses. People in many rural areas, there is lack access to basic healthcare restraining the market growth. Strict regulatory requirements and a shortage of standardization resources in some developed and developing countries are two major factors that are expected hinder Hadron Therapy market growth. The market's growth is expected to be hampered by factors such as a lack of awareness about hadron therapy and a scarcity of therapy providers. In addition, the market's growth is expected to be hampered by the high cost of these therapies.

Hadron Therapy Market Landscape

The Hadron Therapy Market's main strategies include product releases, mergers and acquisitions, joint ventures, and regional expansion. Hadron Therapy Market top 10 companies are Mitsubishi Electric Corporation, Sumitomo Corporation, Mevion Medical Systems, ProTom International, Mitsubishi Electric Corporation, Advanced Oncotherapy, Varian Medical Systems, Inc., Optivus Proton Therapy, Inc., Hitachi, Ltd. and Koninklijke Philips N.V.

Acquisitions/Product Launches

• In January, 2021, ProTom International expanded its business by entering into an exclusive distribution and licensing agreement with Guohong Guokang (Beijing) Health Technology Development Co., LTD ("GHGK"), one of China's leading comprehensive high-tech innovative enterprises, for the distribution of ProTom's Radiance 330® Proton Therapy System in Mainlan. The agreement stipulates that exclusive distribution rights would be granted to a limited number of other countries over time.

Related Reports-

Oncology Market - Forecast(2021 - 2026)

Report Code: HCR 1226

 U.S. Electromagnetic radiation Oncology Market - Forecast(2021 - 2026)

Report Code: HCR 1386

 For more Lifesciences and Healthcare Market reports, please click here